In a Phase 2 clinical trial of olaparib (a lethal PARP inhibitor) as monotherapy against TNBC and ovarian cancer, no significant improvement was observed in the case of TNBC [112]. The gene discussed is PARP1; the disease is ovarian carcinoma.